Coronavirus Infections Clinical Trial
Official title:
Compassionate Use of Opaganib in Patients With Severe COVID-19
Shaare-Zedek Medical Center is a tertiary academic hospital in Jerusalem, Israel. On March 2020, a dramatic increase in the number of COVID-19 cases were diagnosed in Jerusalem. RedHill Biopharma, Ltd. offered opaganib under compassionate use for the treatment of COVID-19 patients. Eligible patients were those hospitalized with COVID-19 confirmed by a reverse-transcriptase-polymerase-chain-reaction assay. Patients received opaganib and Standard of Care. For the purpose of this study, the opaganib and Standard of Care patient group was compared to a group of patients that received only Standard of Care. Opaganib is an investigational drug under development and not approved for commercial distribution.
In this observational study, the two cohorts were assigned retrospectively. Patients either
received opaganib and Standard of Care (SOC) or SOC only. All patients were defined by the
treating physicians at baseline as severe COVID-19. For the control cohort, IRB approval was
granted to collect de-identified data. Both cohorts had similar median age and similar rates
of diabetes, hypertension and obesity.
The two treatment groups, opaganib and SOC vs. SOC were then analyzed for their clinical
outcomes including baseline characteristics.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04553575 -
CoViD-19 Patient in Reims University Hospital in March to April 2020
|
||
Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
Active, not recruiting |
NCT05548439 -
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
|
Phase 1 | |
Completed |
NCT05046548 -
This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05726084 -
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older
|
Phase 2/Phase 3 | |
Recruiting |
NCT05069129 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05054075 -
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
|
Phase 2 | |
Recruiting |
NCT05599516 -
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
|
Phase 3 | |
Completed |
NCT05047900 -
The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community
|
N/A | |
Completed |
NCT04420286 -
Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
|
||
Completed |
NCT04424355 -
Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
|
||
Completed |
NCT05083039 -
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
|
||
Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
Enrolling by invitation |
NCT04327349 -
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
|
N/A | |
Completed |
NCT04321278 -
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
|
Phase 3 | |
Recruiting |
NCT04327570 -
In-depth Immunological Investigation of COVID-19.
|
||
Completed |
NCT04326309 -
Audio Data Collection for Identification and Classification of Coughing
|
||
Recruiting |
NCT04322344 -
Escin in Patients With Covid-19 Infection
|
Phase 2/Phase 3 | |
Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
Completed |
NCT04323592 -
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
|